Myriad Genetic

Forecast & Rating10 analysts currently cover Myriad Genetic, with about 10.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $3.37, about 13.5% downside from the current price of $3.89. Price targets range from $2.00 to $5.00 — a wide spread, showing clear disagreement over just how much Myriad Genetic can rise. Historically, about 74.4% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Myriad Genetic's outlook. Data as of Sep 9, 2026; for reference only and not investment advice.